Abstract:Background Stem cell factor (SCF) and granulocyte-colony stimulating factor (G-CSF) are well-characterized vital hematopoietic growth factors that regulate hematopoiesis. G-CSF and SCF synergistically exhibit a stimulatory effect on hematopoietic progenitors. The combination of G-CSF and SCF has been used for mobilization of peripheral blood progenitor cells in cancer and non-cancerous conditions. To overcome challenges connected with the administration of two cytokines, we developed two fusion proteins composed of human SCF and human G-CSF interspaced by an alpha-helix-forming peptide linker. Methods The recombinant proteins SCF-Lα-GCSF and GCSF-Lα-SCF were purified in three steps using an ion-exchange and mixed-mode chromatography. The purity and quantity of the proteins after each stage of purification was assessed using RP-HPLC, SDS-PAGE, and the Bradford assays. Purified proteins were identified using high-performance liquid chromatography/electrospray ionization mass spectrometry (HPLC/ESI-MS) and the Western blot analyses. The molecular weight was determined by size exclusion HPLC (SE-HPLC). The activity of heterodimers was assessed using cell proliferation assays in vitro. The capacity of recombinant fusion proteins to stimulate the increase of the absolute neutrophil count in rats was determined in vivo. The binding kinetics of the proteins to immobilized G-CSF and SCF receptors was measured using total internal reflection ellipsometry and evaluated by a standard Langmuir kinetics model. Results The novel SCF-Lα-GCSF and GCSF-Lα-SCF proteins were synthesized in Escherichia coli . The purity of the heterodimers reached >90% as determined by RP-HPLC. The identity of the proteins was confirmed using the Western blot and HPLC/ESI-MS assays. An array of multimeric forms, non-covalently associated dimers or trimers were detected in the protein preparations by SE-HPLC. Each protein induced a dose-dependent proliferative response on the cell lines. At equimolar concentration, the heterodimers retain 70–140% of the SCF monomer activity ( p ≤ 0.01) in promoting the M-07e cells proliferation. The G-CSF moiety in GCSF-Lα-SCF retained 15% ( p ≤ 0.0001) and in SCF-Lα-GCSF retained 34% ( p ≤ 0.01) of the monomeric G-CSF activity in stimulating the growth of G-NFS-60 cells. The obtained results were in good agreement with the binding data of each moiety in the fusion proteins to their respective receptors. The increase in the absolute neutrophil count in rats caused by the SCF-Lα-GCSF protein corresponded to the increase induced by a mixture of SCF and G-CSF.

Tuning of granulopoietic signaling by designed agonists

A strategy to design protein-based antagonists against type I cytokine receptors

Tuning Insulin Receptor Signaling Using De Novo Designed Agonists

Topological control of cytokine receptor signaling induces differential effects in hematopoiesis

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist

De novo design of miniprotein antagonists of cytokine storm inducers

Chemical Mutagenesis of a GPCR Ligand: Detoxifying “Inflammo-Attraction” to Direct Therapeutic Stem Cell Migration

Development of Site-Specific PEGylated Granulocyte Colony Stimulating Factor With Prolonged Biological Activity

Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies

Human granulocyte-colony stimulating factor (G-CSF)/stem cell factor (SCF) fusion proteins: design, characterization and activity

Granulocyte colony-stimulating factor directly acts on mouse lymphoid-biased but not myeloid-biased hematopoietic stem cells

Cytokine conjugation to enhance T cell therapy

Design of allosteric modulators that change GPCR G protein subtype selectivity

Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity

Taming the beast: engineering strategies and biomedical potential of antibody-based cytokine mimetics

A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors

Engineering synthetic agonists for targeted activation of Notch signaling

De novo-designed transmembrane domains tune engineered receptor functions

Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors

Synthesis of Osteogenic Growth Peptide and Its Synergetic Effect with Granulocyte Colony Stimulating Factor.